{"id":"auxiliary-medicinal-product-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone acts as a potent corticosteroid that decreases immune cell activation, reduces production of inflammatory mediators (cytokines, chemokines), and stabilizes cell membranes. It is commonly used as an auxiliary agent in oncology trials to manage treatment-related toxicities, particularly immune-related adverse events and inflammation associated with cancer therapies.","oneSentence":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:10.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Auxiliary treatment for management of inflammation and immune-related adverse events in cancer therapy"},{"name":"Supportive care in phase 3 oncology trials (specific indication dependent on parent trial)"}]},"trialDetails":[{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT02592707","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":"Neuroendocrine Tumors","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Auxiliary Medicinal Product - Dexamethasone","genericName":"Auxiliary Medicinal Product - Dexamethasone","companyName":"MedSIR","companyId":"medsir","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Auxiliary treatment for management of inflammation and immune-related adverse events in cancer therapy, Supportive care in phase 3 oncology trials (specific indication dependent on parent trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}